



2022 Statistical Data

CancerCare Center

Minot, North Dakota




TRINITY
HEALTH

Trinity Health Statistics - 2022

There are 15,233 cancer primaries in the Trinity Health cancer registry from 1990 (assessment year) through 2022. This number represents cancer primaries diagnosed and/or treated at Trinity Health.

The following map shows the geographic distribution.

North Dakota - 526 Out-of-State - 14 Total- 540



In 2022, the number of those cases was 540.

According to *Cancer Facts & Figures 2022* from the American Cancer Society, about 80% of all cancers, in the United States, are diagnosed in persons 55 and older.

In 2022, approximately 88% of all cancers diagnosed at Trinity Health were in persons 50 and older.




Age Distribution	Male Total	Female Total
0-29	5	3
30-39	8	16
40-49	13	21
50-59	30	44
60-69	96	67
70-79	87	62
80-89	39	37
90+	4	8
Total	282	258

2022 Trinity Health Leading Sites of New Cancer Cases

These tables demonstrate that the 10 most common malignancies for 2022 at Trinity Health are consistent with those estimated by the American Cancer society as top sites nationwide for 2022. These 10 sites comprised approximately 77% of all malignancies seen at Trinity Health in 2022.

Male

Oral Cavity & Pharynx - 9 (3%)
Lung & Bronchus - 26 (9%)
Pancreas - 7 (2%)
Kidney/Renal Pelvis - 8 (3%)
Urinary Bladder - 27 (10%)
Colon & Rectum - 28 (11%)
Prostate - 80 (28%)
Non-Hodgkin Lymphoma - 8 (3%)
Melanoma of the Skin - 12 (4%)
Leukemia - 9 (3%)
All Other Sites - 68 (24%)



Female

Thyroid - 6 (2%)
Lung & Bronchus - 22 (9%)
Breast - 97 (37%)
Kidney/Renal Pelvis - 2 (1%)
Ovary - 5 (2%)
Uterine Corpus - 17 (7%)
Colon & Rectum - 21 (8%)
Non-Hodgkin Lymphoma - 8 (3%)
Melanoma of the Skin - 14 (5%)
Leukemia - 9 (4%)
All Other Sites - 57 (22%)

2022 Estimates – American Cancer Society

Estimated New Cases*

Male		Female	
Oral Cavity & Pharynx	Prostate	Oral Cavity & Pharynx	Urinary Bladder
38,700 (4%)	268,490 (27%)	15,300 (2%)	19,480 (2%)
Colon	Urinary Bladder	Colon	Kidney & Renal Pelvis
54,040 (5%)	61,700 (6%)	52,140 (6%)	28,710 (3%)
Rectum	Kidney & Renal Pelvis	Rectum	Thyroid
26,650 (3%)	50,290 (5%)	18,200 (2%)	31,940 (3%)
Liver & Intrahepatic Bile Duct	Thyroid	Liver & Intrahepatic Bile Duct	Hodgkin Lymphoma
28,600 (3%)	11,860 (1%)	12,660 (1%)	3,970 (<1%)
Pancreas	Hodgkin Lymphoma	Pancreas	Non-Hodgkin Lymphoma
32,970 (3%)	4,570 (<1%)	29,240 (3%)	36,350 (4%)
Lung & Bronchus	Non-Hodgkin Lymphoma	Lung & Bronchus	Leukemia
117,910 (12%)	44,120 (4%)	118,830 (13%)	24,840 (3%)
Melanoma of the Skin	Leukemia	Melanoma of the Skin	All Sites
57,180 (6%)	35,810 (4%)	42,600 (5%)	934,870 (100%)
Breast	All Sites	Breast	
2,710 (<1%)	983,160 (100%)	287,850 (31%)	

*Rounded to nearest 10; cases exclude basal and squamous cell skin cancers and in situ carcinoma except urinary bladder. About 51,400 cases of female breast ductal carcinoma in situ and 97,920 cases of melanoma in situ will be diagnosed in 2022.